Natera, Inc.

NASDAQ:NTRA

Medical - Diagnostics & Research

Healthcare
$289.50 +0.98%

+$2.23 today

Market cap
$41.98B
Beta
1.54
P/E (TTM)
-143.0
EPS (TTM)
-$1.60
52W Low $131.81High $256.36

Volume 1.96M

Average 1.41M

NTRA Net Income

Bottom-line profit after all expenses, interest, and taxes.

Natera, Inc.NASDAQ: NTRA

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income remains negative

Q2 FY2026 net income was -$66.97M, compared with -$100.94M a year earlier. Trailing-twelve-month net income was -$192.35M.

Context

  • Net income amounted to 9.0% of revenue in FY2025, down 2.2 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 13 analysts of -$236.01M (-13.4%) for the fiscal year ending Dec 2026, a slowdown from the -9.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$66.97M+21.3% QoQ
Last fiscal yearDec 2025
-$208.16M-9.3% YoY
LTMJun 2026
-$192.35M+24.0% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+33.7%+53.8%+20.1 pp
1 year-9.3%-13.4%-4.1 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(208.16M) USD
Year-over-year change
-9.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How NTRA compares with its peers on the latest reported figures

  • NTRA's LTM Jun 2026 net income of -$192.35M is the 7th highest of the 8 companies compared; the peer median is -$73.81M.
  • Its year-over-year change of +24.0% is the 3rd highest of 8, against a peer median of -13.7%.
  • Net income amounts to 7.1% of revenue for NTRA, versus a peer median of 23.4%.
NTRA Competitors Peer median
Net Income for NTRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VCYTVeracyte, Inc.LTM Jun 2026$114.48M +334.7%—20.4%
BLLNBillionToOne, Inc.LTM Jun 2026$33.51M +209.4%—8.4%
SERASera Prognostics, Inc.LTM Mar 2026-$32.14M +2.6%—56386.0%
FLGTFulgent Genetics, Inc.LTM Mar 2026-$73.81M -81.0%—23.0%
PSNLPersonalis, Inc.LTM Mar 2026-$95.55M -13.7%—148.1%
WGSGeneDx Holdings Corp.LTM Jun 2026-$106.36M -7664.5%—23.4%
NTRANatera, Inc.LTM Jun 2026-$192.35M +24.0%—7.1%
MYGNMyriad Genetics, Inc.LTM Mar 2026-$399.9M -294.4%—48.2%
Peer median (excluding NTRA) -$73.81M-13.7%—23.4%

Competitors are the stored peer set for NTRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue625.49M820.22M1.08B1.7B2.31B
Cost of Revenue318.42M456.26M589.83M673.75M810.63M
Gross Profit307.07M363.97M492.74M1.02B1.5B
Gross Margin49.1%44.4%45.5%60.3%64.8%
Research & Development264.21M316.42M320.68M404.14M624.11M
Selling, General & Admin511.03M588.59M618.31M841.31M1.18B
Operating Expenses775.24M905.01M938.99M1.25B1.81B
Depreciation & Amortization11.25M16.7M24.1M30.97M43.48M
EBITDA(451.54M)(520.8M)(397.8M)(148.08M)(220.54M)
EBITDA Margin-72.2%-63.5%-36.7%-8.7%-9.6%
Operating Income(468.17M)(541.04M)(446.25M)(222.29M)(309.91M)
Operating Margin-74.8%-66.0%-41.2%-13.1%-13.4%
Interest Income5.38M3.54M24.35M43.25M45.89M
Interest Expense8.31M9.32M12.64M10.69M4.07M
Other Income / Expenses(2.92M)(5.78M)11.72M32.56M41.82M
Income Before Tax(471.1M)(546.82M)(434.53M)(189.73M)(268.09M)
Pre-Tax Margin-75.3%-66.7%-40.1%-11.2%-11.6%
Income Tax Expense618K978K271K695K(59.93M)
Net Income(471.72M)(547.8M)(434.8M)(190.43M)(208.16M)
Net Margin-75.4%-66.8%-40.2%-11.2%-9.0%
EPS (Basic)(5.21)(5.57)(3.78)(1.53)(1.52)
EPS (Diluted)(5.21)(5.57)(3.78)(1.53)(1.52)
Weighted Avg Shares90.56M98.41M115M124.72M136.72M
Weighted Avg Shares (Diluted)90.56M98.41M115M124.72M136.72M

Natera, Inc.

NASDAQ:NTRA

Intrinsic Alpha fair value

Locked

Current Price

$289.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.